Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Atrinsic Inc. PTIX

Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.

Insider Decisions

Total buys
0.03
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy 1 6
Sell
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
1.27
Revenue
33.49
Net Income
5.46
Free Cash Flow
(2.00)
Net Debt
(0.57)
Current Ratio
0.66
Debt/Equity
0.00
P/E ratio
0.41
P/S ratio
0.00
P/B ratio
0.96
Past 5Y EPS Growth
(10.56%)
This Y EPS Growth
Next Y EPS Growth
Next 5Y EPS Growth
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
Annual Dividend Yield
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 1.84 0.01 1.51 0.57
Receivables 0.07
Inventory 0.00
Other
1.88 0.09 1.54 0.71
2024 2025 2026 Q'26
Payables 0.94 0.96 0.95 1.00
ST’ Debt
Other 1.38
0.94 5.04 1.03 1.07
in millions of $

Compound Annual Growth

10y 5y 3y
Sales
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Year
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (0.94)
’26 0.27 (1.75) (0.81) (0.51)
(2.81)
’25 (1.07)
2.45
’24 (1.66) (3.21) 2.65 (0.35)
(4.22)
’23 (0.37) (1.90) (0.66) (1.14)
(3.70)
’22 (0.43) (1.28) (0.54) (0.18)
(1.99)
’21 (0.61) (1.32) (1.08) (0.41)
(2.80)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (0.94)
’26 0.26 (1.75) (0.81) (0.51)
(2.81)
’25 (1.07)
2.45
’24 (1.66) (3.21) 2.59 (0.51)
(4.22)
’23 (0.37) (1.90) (0.71) (1.24)
(3.85)
’22 (0.43) (1.28) (0.54) (0.18)
(2.00)
’21 (0.61) (1.32) (1.08) (0.41)
(2.80)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.53)
’26 2.09 (1.37) (0.47) 1.14
0.59
’25 (2.75)
(15.83)
’24 (5.46) (5.04) (1.96) (3.36)
(15.83)
’23 (2.38) (3.92) (4.48) (5.32)
(16.11)
’22 (4.48) (2.24) (2.80) (0.14)
(0.82)
’21 (6.16) (6.16) (2.80) (2.80)
(17.37)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ 18.48 9.52 6.16 1.12 0.13
Low Price
‡‡‡‡‡ 82.88 35.28 26.18 14.28 1.32
High Price
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 2 3 3 2
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00
Revenue/Emp
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00%
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.56) (5.00) (5.53) (3.59) 1.37
EBT
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% 0.00%
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.56) (5.00) (5.53) 1.93 1.37
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.11 0.11 0.05 0.55 1.62
Depreciation
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 0.00
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11.56) (16.11) (15.83) (15.83) 0.59
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.47) (11.94) (12.05) 0.46 (1.21)
Cash Flow/Sh
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ (0.01) (0.48) 0.00 0.00 0.00
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.47) (12.42) (12.05) 0.46 (1.21)
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.44 11.83 2.90 (0.92) 1.12
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.31 0.31 0.35 5.37 2.33
Shares
PE Ratio
PS Ratio
PB Ratio
EV/Sales
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.99) (3.70) (4.22) 2.45 (2.81)
Op' Cash Flow
0.00 (0.15) 0.00
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.00) (3.85) (4.22) 2.45 (2.81)
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.92 3.54 0.94 (4.95) 0.51
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.34
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (7.63) (4.06) (1.84) (0.01) (1.51)
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.92 3.67 1.01 (4.95) 2.62
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (37.24%) (80.91%) (175.98%) (351.29%) 73.16%
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% (253.66%)
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (42.18%) (94.48%) (236.06%) 182.34% (117.22%)
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Atrinsic Inc. (PTIX) presents a complex financial narrative characterized by persistent challenges and cautious optimism for future transformation. Over the past decade, the company has struggled with negative earnings, with 2023 showing a net loss of approximately $5 million, a 40% increase from the previous year. Revenue generation has been stagnant, with zero revenue per employee and minimal workforce, raising concerns about operational activity and market capitalization. The negative cash flow per share and negligible capital expenditure further highlight the company’s financial struggles and limited growth prospects.

Despite these challenges, there are signs of financial management improvements, such as a reduction in net debt and positive working capital. However, the stock price of $0.37 starkly contrasts with the analyst price target of $16, suggesting potential upside if operational and financial issues are addressed. The lack of insider trading activity could indicate either a lack of confidence or a period of stability. Looking forward, analyst predictions for 2024 suggest a potential turnaround with improved earnings per share, indicating strategic investments or expansions. Investors should closely monitor Atrinsic’s strategic initiatives and approach investment with caution, given the significant risks and opportunities presented by the company’s financial situation.

Atrinsic Inc. (PTIX) Latest News

News by impact score

Fine-tune

20 Aug

4 , 8:30 AM
Protagenic Therapeutics received supportive FDA pre-IND feedback enabling a new IND filing for PT00114 in generalized anxiety disorder. FDA clearance to file IND for PT00114 advances drug development and can materially lift company trajectory and investor sentiment.

30 Jun

3 , 8:30 AM
PT00114, Protagenic Therapeutics' lead candidate, attenuated chronic stress responses in a well-established rodent model. Positive preclinical rodent data on PTIX lead candidate signals moderate pipeline progress with limited immediate market effects.

23 Apr

4 , 8:15 AM
Protagenic Therapeutics (PTIX) appoints industry veteran Bill Nichols Jr. as President to accelerate advancement of first-in-class TCAP pathway therapy PT00114. Appointing an industry veteran as President to fast-track a first-in-class therapy constitutes a major strategic leadership change with potential to significantly enhance PTIX's development momentum and investor confidence.

17 Mar

4 ACCESS Newswire, 8:00 AM
Protagenic Therapeutics completes Phytanix separation, strengthens balance sheet, and repositions around PT00114. Subsidiary separation, balance sheet strengthening, and refocus on lead candidate PT00114 enable major strategic repositioning.

10 Mar

3 ACCESS Newswire, 8:00 AM
Protagenic Therapeutics (PTIX), formerly Atrinsic Inc., upgrades its stock listing from OTC Pink to the higher-standard OTCQB Venture Market, improving visibility, reporting requirements, and investor access. The OTCQB upgrade boosts credibility and market visibility for PTIX, likely influencing investor sentiment and liquidity moderately without fundamentally transforming operations.

9 Dec

3 ACCESS Newswire, 8:46 AM
Atrinsic Inc. (PTIX) announced results from a Phase 1 multiple-dose study of PT00114, demonstrating its safety and tolerability in healthy subjects. The study aimed to evaluate the pharmacokinetics and pharmacodynamics of the drug, which targets specific conditions. Initial findings indicate promising outcomes that may support further development and potential market introduction. The results from the Phase 1 study may influence future product development and market positioning for PTIX.

27 Nov

3 ACCESS NewswireMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires, 3:45 AM
Protagenic Therapeutics has received a non-compliance notice from Nasdaq due to its failure to maintain a minimum bid price of $1 per share for 30 consecutive trading days. The company has a 180-day compliance period to regain compliance, which can be extended if certain conditions are met. Failure to comply may result in delisting from the exchange. The non-compliance notice may affect investor sentiment and stock performance, but the company has time to address the issue.

13 Nov

3 ACCESS Newswire, 8:22 AM
Protagenic Therapeutics has completed enrollment and dosing in its Phase 1 Multiple Ascending Dose (MAD) study, which is a significant step in the clinical development of its therapeutic candidates. This study aims to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. The completion of this phase is crucial for advancing the drug towards further clinical trials and potential market introduction. Completion of the Phase 1 MAD study may moderately influence future product development and investor sentiment.

22 Aug

3 , 5:25 PM
Protagenic Therapeutics announced an update regarding its Form 10-Q filing timeline and compliance with Nasdaq requirements. The company is actively working to meet the necessary deadlines and maintain its listing status on the exchange. Further details on the specific timeline and any potential implications for shareholders were provided. Compliance with Nasdaq requirements can moderately influence investor sentiment and the company's market position.

21 Aug

4 , 8:12 AM
Protagenic Therapeutics has advanced its drug candidate PT00114 into a multiple-dose Phase 1 trial, aiming to position itself for a Phase 2 trial targeting stress and mood disorders. This progression indicates a significant step in the development of PT00114, which could address unmet needs in mental health treatment. Advancing PT00114 into a Phase 1 trial represents a significant strategic move that could enhance the company's market position and investor sentiment.

3 , 1:54 PM
Atrinsic Inc. (PTIX) has been identified as one of the top midday gainers in the market, reflecting a notable increase in its stock price. This surge may indicate positive investor sentiment or market interest in the company's recent developments or performance. The stock's rise suggests a moderately noticeable influence on market sentiment and potential financial performance.

3 , 10:30 AM
Atrinsic Inc. (PTIX) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company. Investors are closely monitoring PTIX for potential opportunities or risks associated with its stock performance. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential short-term performance.

30 Jul

3 , 8:30 AM
Protagenic Therapeutics has been granted a new patent in Japan for its Modified Stilbenoid Program drug candidates, which aims to enhance therapeutic options in various medical fields. This patent is expected to strengthen the company's intellectual property portfolio and support its ongoing research and development efforts. The patent grant may enhance product innovation and competitive positioning, but its overall impact on financial performance is expected to be limited.

21 May

3 , 9:15 AM
Protagenic Therapeutics has raised $3.1 million through recent warrant activity, enhancing its financial position. The funds are expected to support ongoing development efforts and operational needs, potentially positioning the company for future growth. The funding from warrant activity may moderately influence financial performance and operational capabilities.

19 May

3 , 7:43 AM
Protagenic Therapeutics and Phytanix have announced a business combination to create a new neuroactive biopharmaceutical company. This merger will focus on developing six drug candidates, including treatments for obesity and metabolic disorders, aiming to enhance their market position and product offerings. The merger may moderately influence Atrinsic Inc.'s competitive positioning and market sentiment due to the focus on drug candidates relevant to metabolic health.

29 Apr

3 ACCESS Newswire, 4:00 PM
Protagenic Therapeutics, Inc. (Nasdaq:PTIX) announced a 1-for-14 reverse stock split effective May 5, 2025, to comply with Nasdaq's minimum bid price requirement. The split will reduce the number of outstanding shares from approximately 8.24 million to about 588,750. Stockholders will receive information regarding their shares post-split, and adjustments will be made to equity awards and incentive plans. The company's stock will continue to trade under the symbol 'PTIX' with a new CUSIP number. The reverse stock split is a strategic move to maintain compliance with Nasdaq listing requirements, which may influence market perception and stock performance.

5 Nov

3 ACCESSWIRE, 8:12 AM
Protagenic Therapeutics closed a private placement, raising $1.275 million for working capital purposes. The private placement is expected to moderately influence the company's financial performance and competitive positioning.

29 Oct

3 ACCESSWIRE, 9:27 AM
Protagenic Therapeutics, Inc. announced a private placement offering for gross proceeds of $1.275 million, with plans to use the funds for working capital purposes. The private placement offering is expected to moderately influence the company's financial performance and competitive positioning.

22 May

4 ACCESSWIRE, 8:12 AM
Protagenic Therapeutics reports exceptional safety in Phase I trial for stress-regulating peptide PT00114, paving the way for potential breakthrough treatments in stress-related neuropsychiatric disorders. The safety data from the trial could lead to significant advancements in treating stress-related disorders and have a profound impact on Atrinsic Inc.'s future prospects.

1 May

4 ACCESSWIRE, 8:38 AM
Protagenic Therapeutics completes enrollment in Phase 1 trial for PT00114 synthetic stress-regulating peptide. The completion of enrollment in the Phase 1 trial for a potential transformative treatment for neuropsychiatric disorders could significantly impact Atrinsic Inc.'s future and market performance.

17 Apr

4 ACCESSWIRE, 8:42 AM
Protagenic Therapeutics COO to present on PT00114 at Peptide Therapeutics Summit in Boston. Presentation on innovative drug candidate with potential to impact company's future and market performance significantly.

1 Apr

4 ACCESSWIRE, 4:20 PM
Protagenic Therapeutics reports progress in Phase 1 clinical trial for PT00114, a neuropeptide drug candidate for stress-related neuropsychiatric disorders. The progress in the Phase 1 trial for PT00114 has the potential to significantly impact Atrinsic Inc.'s future and market performance.

27 Mar

4 ACCESSWIRE, 8:42 AM
Protagenic Therapeutics completes third cohort in Phase 1 trial for stress-related neuropsychiatric disorders. Successful completion of Phase 1 trial for potential transformative therapy could significantly impact Atrinsic Inc.'s future.

25 Mar

3 ACCESSWIRE, 5:00 PM
Protagenic Therapeutics schedules first Q4 and FY 2023 earnings call for April 1st, 2024 at 4:30 pm ET. The earnings call may moderately influence investor sentiment and financial performance.

13 Feb

4 ACCESSWIRE, 8:30 AM
Protagenic Therapeutics achieves safety milestone in Phase I trial for PT00114, a novel neuropeptide for stress-related disorders. The successful safety milestone achievement in the Phase I trial for a novel neuropeptide could significantly impact Atrinsic Inc.'s future and market performance.

13 Oct

3 ACCESSWIRE, 9:00 AM
Protagenic Therapeutics, Inc. announces date of annual shareholder meeting. The announcement of the annual shareholder meeting may moderately influence investor sentiment and the company's competitive positioning.

26 Sep

4 ACCESSWIRE, 8:18 AM
Protagenic Therapeutics initiates Phase I/IIa clinical trial for groundbreaking brain peptide PT00114. The initiation of a Phase I/IIa clinical trial for a novel brain peptide with potential to treat stress-related neuro-psychiatric disorders could have a significant impact on Atrinsic Inc.'s future and market performance.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us